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IMPORTANCE Psychotic disorders are characterized by attenuated activity in the brain’s
valuation system in key reward processing areas, such as the ventral striatum (VS), as
measured with functional magnetic resonance imaging.
OBJECTIVE To examine whether common risk variants for psychosis are associated with
individual variation in the VS.
DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study of a large cohort of adolescents
from the IMAGEN study (a Europeanmulticenter study of reinforcement sensitivity in
adolescents) was performed fromMarch 1, 2008, through December 31, 2011. Data analysis
was conducted fromOctober 1, 2015, to January 9, 2016. Polygenic risk profile scores (RPSs)
for psychosis were generated for 1841 healthy adolescents. Sample size and characteristics
varied across regression analyses, depending onmutual information available (N = 1524-
1836).
MAIN OUTCOMES ANDMEASURES Reward-related brain functionwas assessedwith blood
oxygen level dependency (BOLD) in the VS using themonetary incentive delay (MID) task,
distinguishing reward anticipation and receipt. Behavioral impulsivity, IQ, MID task
performance, and VS BOLDwere regressed against psychosis RPS at 4 progressive P
thresholds (P < .01, P < .05, P < .10, and P < .50 for RPSmodels 1-4, respectively).
RESULTS In a sample of 1841 healthy adolescents (mean age, 14.5 years; 906 boys and 935
girls), we replicated an association between increasing psychosis RPS and reduced IQ (matrix
reasoning: corrected P = .003 for RPSmodel 2, 0.4% variance explained), supporting the
validity of the psychosis RPSmodels. We also found a nominally significant association
between increased psychosis RPS and reducedMID task performance (uncorrected P = .03
for RPSmodel 4, 0.2% variance explained). Our main finding was a positive association
between psychosis RPS and VS BOLD during reward anticipation at all 4 psychosis RPS
models and for 2 P thresholds for reward receipt (RPSmodels 1 and 3), correcting for the
familywise error rate (0.8%-1.9% variance explained).
CONCLUSIONS AND RELEVANCE These findings support an association between psychosis RPS
and VS BOLD in adolescents. Genetic risk for psychosis may shape an individual’s response to
rewarding stimuli.
JAMA Psychiatry. 2016;73(8):852-861. doi:10.1001/jamapsychiatry.2016.1135
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P sychoticdisordersshareconsiderablegeneticvariance1,2andhaveconsiderableoverlapintheclinicalphenotype.3There is thus increasing interest in biological and psy-
chologicalmechanismsthatmayoperateacross thesedisorders.
Attempts tounifymechanisms inpsychosisusemethods such
asmagnetic resonance imaging (MRI) toexplore theneural cir-
cuits that aredisrupted inpsychosis.4-6 Psychosis is character-
ized by changes in reward valuation systems and underlying
frontostriatalcircuitry.7-11Arecentmeta-analysis12 suggests that
psychosis is associatedwith alterations in ventral striatal (VS)
blood oxygen level dependency (BOLD), suggesting that VS
BOLDduringrewardprocessingmaybeacandidatemechanism
bywhich psychosis susceptibilitymanifests. This hypothesis
is also supported by associations betweenVSBOLDandnega-
tive symptoms (see themeta-analysis by Radua et al12). Stud-
ieshave further found that rewardprocessing isheritable13 and
altered in relativesofpatientswithpsychosis,14 suggesting that
genetic riskmay contribute to VS BOLD.
Individual genetic risk loci confer small amounts of
susceptibility1;however, riskprofile scores (RPSs)explain larger
proportions of variance for psychosis and can be used to pre-
dict variance in related phenotypes.1 We recently found that
a schizophrenia RPS was associated with an attenuated VS
BOLD responseduring aprobabilistic learning task,15 suggest-
ing that the cumulative effect of risk single-nucleotide poly-
morphismswas associatedwith the VS BOLD alterations pre-
viouslyobserved inpatientswithpsychosis16-18 andunaffected
relatives.19 However, it is currently not knownwhether poly-
genic riskofpsychoticdisorders is associatedwith rewardpro-
cesses, such as anticipation and receipt, as assayed using the
monetary incentive delay (MID) task.20 The MID task assays
BOLD during incentive processing and is relatively indepen-
dentof reward-based learning (participants learn thestimulus-
reward associations before scanning)21 comparedwithproba-
bilistic learningparadigms,which assay an individual’s ability
to dynamically update assumptions based on choice behav-
ior andoutcomes.15,22 Theputative absenceof a learning com-
ponent within the MID paradigm will address whether the
psychosis RPS is associatedwith affective salience toward re-
ward. To answer this question,we used the IMAGEN23 cohort
(http://www.imagen-europe.com/) to probe VS BOLD for
associations with the psychosis RPS. We initially assayed the
psychosisRPS rather thanschizophrenia andbipolar summary
data sets because (1) in a sample of healthy adolescents, we
replicatedanassociationbetweenincreasingpsychosisRPSand
reduced IQ12; (2) we hypothesize that VS BOLDwill be linked
to the genetic risk that is shared between schizophrenia and
bipolar disorder; (3) we aimed to reduce the number of RPS
comparisons; and (4) recent success has linkedpsychosis RPS
to other imaging phenotypes.24
On the basis of a previousmeta-analysis,12 we anticipated
that the psychosis RPSwould be associatedwith reductions in
VS BOLD during reward anticipation in the MID task and to a
lesser extent during reward receipt, mirroring the findings in
peoplewithmanifestpsychosis.12WealsousedapsychosisRPS
approach toprobe for putative associationwith (1) intelligence
using theWechsler Intelligence Scale for Children–Fourth Edi-
tion (WISC-IV),25 (2) behavioral impulsivity using a delay dis-
counting paradigm,26 and (3)MID task performance.We assay
intelligence toensure that theputativepsychosisRPSeffectson
reward are independent of intelligence. Thedelay discounting
paradigm quantifies an individual’s ability to delay gratifica-
tion,aphenotypethat isheritable27andalteredinpsychosis.28,29
Using a psychosis RPS approach, we sought to determine
whether psychosis RPS was associated with these pheno-
types. Together, we anticipate that these regressions will help
elucidate how common risk for psychosis may affect reward
systems in the adolescent brain.
Methods
Participants
We analyzed data from the IMAGEN project, a well-
characterized, European,multicenter, genetic-neuroimaging
study in adolescence23 (Table 1). Participants were recruited
fromMarch 1, 2008, throughDecember 31, 2011, through sec-
ondary schools at 8 sites located in England, France, Ireland,
and Germany. Data analysis was conducted from October 1,
2015, to January 9, 2016. The IMAGEN project had obtained
ethical approval by the local ethics committees andwritten in-
formed consent from all participants and their legal guard-
ians. Standard operating procedures for IMAGEN are avail-
able at http://www.imagen-europe.com/en/Publications_and
_SOP.php.All individualswerescreenedformagnetic resonance
contraindicationsandmedical conditions.Allparticipantswere
assessed for psychopathologic conditions aspart of a scale tai-
lored toadolescentsandbasedon InternationalStatisticalClas-
sification ofDiseases, 10thRevision (ICD-10), aswell asDSM-IV
(Development andWell-BeingAssessment Interview). Partici-
pants were excluded based on the presence of schizophrenia
or bipolar disorder, neurodevelopmental disorders (such as
autism), or an IQ of less than 70 (for further exclusion crite-
ria, see the Supplement in the article by Schumann et al23).
Genetic Data
To ensure high quality and sufficient quantity, we semiauto-
matedDNAextraction.8The IlluminaQuad610chip (Illumina
Inc) was used for genome-wide genotyping of approximately
600000 autosomal single-nucleotide polymorphisms.
As part of the IMAGEN project, DNA was extracted from
blood samples. Genotyping methods and quality control de-
Key Points
Question Do common genetic risk alleles for psychosis contribute
to reward processing in adolescents?
Findings In a study of the IMAGEN cohort of 1528 adolescents,
common genetic risk alleles for psychosis explain approximately
1% to 2% of the variance in reward processing in the ventral
striatum (as measured using functional magnetic resonance
imaging).
Meaning Common genetic risk for psychosis may shape an
individual’s response to rewarding stimuli.
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tails can be found in the eMethods in the Supplement. After
qualitycontrol,502 160single-nucleotidepolymorphismswere
considered for the psychosis RPS score calculation in 1841 in-
dividuals (for whom demographic data were also available).
Generation of RPSs
Psychosis RPSs were calculated using the method described
by the International Schizophrenia Consortium.30 Psychosis
genetic riskwasestimatedusingpublicly available resultsdata
froman international genome-wideassociationstudyof 19779
patients with psychosis and 19423 controls.1 For a descrip-
tion of themethods used to calculate the psychosis RPSs and
the characteristics of thepsychosisRPSs in the sample, see the
eMethodsandeFigure 1 in theSupplement. Inaposthocanaly-
sis,we estimatedRPSs for schizophrenia andbipolar disorder
separately using available summary statistics for schizophre-
nia and bipolar generated by the Cross-Disorder Group of the
Psychiatric Genomics Consortium.31
Intelligence, Behavioral Impulsivity, and Psychopathology
We measured IQs using the WISC-IV.25 We tested psychosis
RPSs against 4 parameters (similarities, vocabulary, block de-
sign, matrix reasoning) and used them as covariates to con-
trol for potential confounding IQ effects in the psychosis RPS
regressions on reward function (delay discounting, behav-
ioral MID, reward anticipation, and receipt). Delay discount-
ing was measured with the questionnaire designed by Kirby
andMaraković,26,32 using a series of 27 choices between a hy-
pothetic smaller, sooner and a larger, later reward. We com-
puted a subjective discount parameter (k) as previously
described.29 The k values were log transformed before the
analyses toaccount foraskeweddistribution.BecauseVSBOLD
has been associated with other phenotypes, such as depres-
sive symptoms33 and smoking behavior,34 we additionally
screened for depressive symptoms (which were rated using
the Development and Well-Being Assessment Interview
with a computerized diagnostic algorithm that predicts the
likelihood of a clinical diagnostic rating35) and smoking
behavior (measured using the Fagerström Test for Nicotine
Dependence36).
Monetary Incentive DelayMRI Task
Participantsperformedamodifiedversionof theMID task20,37
during scanning. Details of the paradigm are detailed in the
eMethods in the Supplement.
MRI Data Acquisition and Preprocessing
Images were processed as previously described by IMAGEN
consortium23 (eMethods in the Supplement). Because of our
apriori hypothesesof associationsbetweenpsychosisRPSand
VS BOLD, which is consistently recruitment during the MID
task,34,38 we tested our hypothesis solely in this region of in-
terest. The VS masks were composed of 9-mm spheres cen-
tered at the x, y, and z values of −14, 8, and −8 and 14, 8, and
−8, respectively (Montreal Neurological Institute coordi-
nates), for the left and right VS as previously described.21,38
Power Analysis
Using the methods outlined by Dudbridge,39 we had 80%
power to detect an effect ranging from0.044% to 0.052% ex-
plained variance (eMethods in the Supplement).
Statistical Analysis
We ranmultiple regression for the 4WISC-IV variables, delay
discounting in R version 3.0.2 (https://cran.r-project.org/),
where the log-transformed hyperbolic discounts (log k)
function as the dependent variables and psychosis RPS as the
independent variable at 4progressiveP thresholds (P< .05 for
RPSmodel 1, P < .05 for RPSmodel 2, P <.10 for RPSmodel 3,
and P < .50 for RPS model 4). These progressive P thresholds
explain themostvariance in theclinicalphenotype.1Wecorrect
for the number of multiple comparisons across P thresholds
using the false discovery rate. Each regressionwas controlled
for age, sex, testing site, IQ (measured by the 4 WISC-IV
variables), and the first 5 principle components (from the
variance-standardized relationship matrix of the linkage
disequilibrium–pruned genotypes) to account for ancestry
admixture (population stratification) and potential
relatedness.40We repeated these regressions (using the same
covariatesas thedelaydiscounting regression) for theMIDtask
performance (asmeasured by number of successful attempts
Table 1. Sample Size for Each Psychosis Risk Profile Score Regression Analysis
Variable
Sample
Size, No. Age, Mean (SD), y
Male/Female,
No.
Mean (SD)
Finding
IQ (WISC-IV)
Block design 1835 14.52 (0.90) 903/932 50.51 (9.51)
Vocabulary 1833 14.52 (0.90) 902/931 49.87 (8.46)
Matrix reasoning 1835 14.52 (0.90) 903/932 26.41 (4.03)
Similarities 1836 14.52 (0.90) 903/933 30.39 (5.59)
Reward (behavior)
Delay discounting (log k) 1822 14.52 (0.90) 927/895 −1.88 (0.61)
MID (No. of successful trials, maximum
of 22 per reward level)
1732 14.51 (0.92) 856/876 13.76 (1.95)
MID (No. of early responses) 1737 14.51 (0.91) 857/880 0.11 (0.1)
Reward (fMRI)
Anticipation 1528 14.56 (0.45) 740/788 NA
Receipt 1559 14.56 (0.45) 769/790 NA
Abbreviations: fMRI, functional
magnetic resonance imaging;
MID, monetary incentive delay;
NA, not applicable; WISC-IV, Wechsler
Intelligence Scale for Children–Fourth
Edition.
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to obtain reward andproportionof early responses) and in the
neuroimaging data, using SPM8 software (http://www.fil.ion
.ucl.ac.uk/spm/software/spm8/), where the dependent
variableswereVSBOLDduringrewardanticipationandreceipt.
We controlled for multiple testing across the VS search space
using familywise error correction (P < .05).
Results
Psychosis RPS and IQ
We found nominally significant negative associations be-
tween the psychosis RPS andWISC-IV variables (uncorrected
block design and corrected matrix reasoning) across all P
thresholds.Noassociationswere foundbetweenpsychosisRPS
and delay discounting when controlling for age, sex, testing
site, WISC-IV variables, and the first 5 principle components
(Table 2).
Psychosis RPS andMID Task Performance
Wefoundanominally significant associationbetween thepsy-
chosis RPS and behavioral performance in the MID task. The
psychosis RPS was negatively associated with the number of
successful attempts and an increased proportion of early re-
sponses, explaining 0.18% to 0.27% of the variance, after ad-
justing for covariates (Table 3).
Table 2. Associations Between Psychosis RPS andWISC-IV Variablesa
WISC-IV Variable and Psychosis RPS Model R2 β P Value
Block design (n = 1835)
RPS model 1 0.0017 −0.05 .04
RPS model 2 0.0020 −0.06 .03
RPS model 3 0.0029 −0.05 .01
RPS model 4 0.0019 −0.05 .03
Vocabulary (n = 1833)
RPS model 1 −0.0005 −0.008 .75
RPS model 2 −0.0005 0.007 .90
RPS model 3 −0.0005 −0.003 .77
RPS model 4 −0.0001 0.02 .38
Matrix reasoning (n = 1835)
RPS model 1 0.0035 −0.06 .006
RPS model 2 0.0042 −0.06 .003
RPS model 3 0.0034 −0.07 .007
RPS model 4 0.0024 −0.05 .02
Similarities (n = 1836)
RPS model 1 0.0003 −0.03 .21
RPS model 2 −0.0005 0.009 .88
RPS model 3 −0.0005 0.004 .70
RPS model 4 0.0000 0.02 .30
Log K (n = 1822)
RPS model 1 −0.0003 0.02 .46
RPS model 2 −0.0002 0.02 .40
RPS model 3 −0.0005 0.001 .96
RPS model 4 −0.0005 0.004 .86
Abbreviations: RPS, risk profile score;
WISC-IV, Wechsler Intelligence Scale
for Children–Fourth Edition.
a Associations were adjusted for age,
sex, testing site, and the first 5
principal components. The log κ
values were adjusted for the same
covariates and the 4 WISC-IV
variables. Associations that survive
correction for multiple comparisons
(false discovery rate) are in bold.
Table 3. Associations Between Psychosis RPS and Behavioral Performance in theMID Task
MID Task and Psychosis RPS
Model R2 β P Value
Success (n = 1732)
RPS model 1 −0.00015 −0.02 .39
RPS model 2 0.00002 −0.02 .31
RPS model 3 0.00089 −0.04 .11
RPS model 4 0.00204 −0.05 .03
Early responses (n = 1737)
RPS model 1 −0.00057 −0.003 .89
RPS model 2 0.00036 0.03 .20
RPS model 3 0.00182 0.05 .04
RPS model 4 0.00270 0.06 .02
Abbreviations: MID, monetary
incentive delay; RPS, risk profile
score.
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Group Effects of Reward Anticipation and Receipt
Whole group (1-sample t test) effects are documented in
eFigure 2 and the eResults in the Supplement.
Psychosis RPS and Reward Anticipation
We found a positive association between psychosis RPS and
VS BOLD at all 4 thresholds (Table 4 and Figure, A). No nega-
tive associations were found between the psychosis RPS and
VS BOLD after controlling for the familywise error across the
VS region of interest. To explore the effects of extreme poly-
geneticity (comparing individuals with the highest psychosis
RPS and individuals with the lowest psychosis RPS), we split
thewhole sample into 10deciles (as previousdescribed41) and
explored thedifferencebetweendecile 1 (lowestpolygenic risk)
and decile 10 (highest polygenic risk) for parameter esti-
mates extracted fromthe significant clusters (Cohend = 0.43;
95% CI, 0.203-0.658, for RPSmodel 1; Cohen d = 0.476; 95%
CI, 0.248-0.703, for RPS model 2; Cohen d = 0.492; 95%
CI, 0.264-0.72, for RPS model 3; and Cohen d = 0.438; 95%
CI, 0.21-0.665, for RPS model 4). All effects were significant
after controlling for comparisons among the 10 deciles (cor-
rected P < .001 in all cases).
Psychosis RPS and Reward Receipt
WefoundapositiveassociationbetweenthepsychosisRPSand
VS BOLD for RPS models 1 and 3 (Table 4 and Figure, B). No
negative associationswere found between the psychosis RPS
and VS BOLD after controlling for the familywise error across
the VS region of interest. We split the whole sample into 10
deciles and looked at the differences betweendecile 1 (lowest
polygenic risk) and decile 10 (highest polygenic risk) for pa-
rameter estimates extracted from the significant clusters (Co-
hen d = 0.395; 95% CI, 0.171-0.62, for RPS model 1; Cohen
d = 0.227;95%CI, 0.004-0.45, forRPSmodel3);however.only
theeffect identifiedat theRPSmodel 1 threshold remainedsig-
nificant after correcting for multiple comparisons (corrected
P = .007).
Depressive Symptoms and Smoking Behavior
A positive association was found between psychosis RPS and
number of depressive symptoms (t9,1817 = 2.965, P = .003, for
RPSmodel 4). However, no associationswere found between
depressive symptoms and the 6 VS BOLD parameter esti-
mates (P > .40 in all cases), and the association between the
psychosis RPS andVSBOLDdid not significantly change after
controlling fordepressivesymptoms.Noassociationwas found
with smoking behavior and (1) the psychosis RPS (P > .30 in
all cases) and (2) the 6 VS BOLD parameter estimates (P > .10
in all cases).
Contribution of Schizophrenia and Bipolar
to Psychosis RPS Effects
The associationbetween thepsychosisRPS andWISC-IVvari-
ables (block design and matrix reasoning) was driven exclu-
sively by the schizophrenia RPS. We did not observe a spe-
cific effect of the schizophrenia or bipolar RPS on MID task
performance (success and reaction time). However, VS BOLD
was influencedbyschizophreniaandbipolarRPS (eResults and
eTable in the Supplement).
Discussion
Weobservedand replicated associationsbetween thepsycho-
sis RPS and reduced performance IQ,42-44 supporting the va-
lidity of the psychosis RPS approach. Post hoc analysis re-
vealed that this association was driven by the schizophrenia
RPS.Additional support for thepsychosisRPSmodelcamefrom
evidencesupportinganassociationbetweenthepsychosisRPS
and task performance during the MID task, although this as-
sociation did not withstand correction for multiple compari-
sons, and we could not find a specific contribution from the
schizophrenia or bipolar RPS. We also did not observe an as-
sociation between the psychosis RPS and behavioral impul-
sivity, asmeasured using a delay discounting paradigm. Con-
sistentwith ourmainhypothesis,weobserved an association
between thepsychosis RPS andVSBOLD.Consistentwith our
originalhypothesis, theassociationbetweenthepsychosisRPS
andVS BOLDwas driven by the RPS for schizophrenia and bi-
polar disorder. These findings support previous associations
between common psychosis risk loci (ODZ4, CACNA1C) and
reward processing.45,46 Furthermore, we build on previous
Table 4. Significant Voxel Clusters From the Psychosis RPS Regression During Reward Anticipation and Receipt, Controlling
for Covariates, Across 4 Progressive P Thresholds
P Threshold κ MNI Coordinates (x, y, z) z
Familywise
Error P R2 β
Reward anticipation
RPS model 1 7 −12,2, − 8 3.91 .01 0.008 0.10
RPS model 2 11 −12,2, − 8 4.70 .001 0.019 0.14
RPS model 3 11 −18,1, − 8 4.48 .001 0.017 0.14
RPS model 4 6 −18,2, − 5 3.95 .009 0.013 0.12
Reward receipt
RPS model 1 NA NA NA NA NA NA
RPS model 2 1 −9,5, − 8 3.33 .05 0.010 0.10
RPS model 3 NA NA NA NA NA NA
RPS model 4 3 −18, − 1, − 8 3.61 .02 0.009 0.10
Abbreviations: κ, number of contiguous voxels; MNI, Montreal Neurological Institute; NA, not applicable; RPS, risk profile score.
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work15 that suggested that the schizophrenia RPS is associ-
atedwith altered reward processing in healthy individuals. A
previous study12 suggests that psychosis is characterized by
VS hypoactivation, whichmight relate to negative symptoms
that underpin psychosis. However, other studies have sug-
gested that type 2 bipolar disorder and adolescent bipolar
disorder are associated with frontostriatal BOLD signal dur-
ing reward anticipation47-49 and that relatives of patientswith
schizophreniahave increasedVSBOLDduringrewardreceipt.19
In linewith themeta-analysis,12 themost prominent associa-
tionbetweenpsychosisRPS andVSBOLDoccurredduring the
reward anticipation phase, suggesting that risk for psychosis
may alter disrupt incentive motivation and reward salience.
The receipt phase could also be less sensitive to VS activation
(because of variable success rates), which could explain the
weaker association with the psychosis RPS. One key differ-
ence between our study and the studies included in the
meta-analysis12 of patients with psychosis is that our sample
had amean age of 14.5, whereas themean age of the patients
in themeta-analysiswasapproximately30years.Thishypoth-
esis is supported by recent evidence supporting an age × VS
BOLD interaction in adolescents with genetic risk for schizo-
Figure. Coronal Sections atMontreal Neurological Institute Coordinate y = 5
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Positive associations between the psychosis risk profile score (RPS) and blood
oxygen level dependency (BOLD) in the ventral striatum (VS) during reward
anticipation and reward receipt at 4 progressive P thresholds (P < .01 for RPS
model 1, P < .05 for RPSmodel 2, P < .10 for RPSmodel 3, and P < .50 for RPS
model 4), controlling for age, sex, testing site, Wechsler Intelligence Scale for
Children–Fourth Edition variables, and the first 5 principal components
(n = 1528 and 1559, respectively). All clusters are corrected for the familywise
error across the bilateral VS (P < .05). Plots on the right show themean
psychosis RPSs across 10 deciles plotted against BOLD parameter estimates in
the significant clusters identified in themultiple regression. Note that the 10
deciles reflect the data extracted from the clusters within the VS, which
remained significant and are purely for illustration purposes. Error bars indicate
95% CI. AU indicates arbitrary units; L, left hemisphere; NS, nonsignificant.
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phrenia, where younger adolescent offspring have increased
VSBOLDduring theMID task, but older adolescents offspring
haveattenuatedVSBOLD.50Genetic riskofpsychosismayhave
different effects on brain physiologic mechanisms across the
lifespan and leads to enhanced incentive salience in adoles-
cence, which is attenuated during later stages of neurodevel-
opment. This finding is supported by a recentmeta-analysis51
that found that, comparedwithadults, adolescents (meanage,
14.1 years) have increased VS BOLD during reward process-
ing, which is attributed to increased motivated activity dur-
ingadolescence.ThedifferentdirectionofalteredVSBOLDmay
also be explainedby state effects (such asmedication anddis-
ease chronicity).
Althoughourdata suggest anassociationbetween thepsy-
chosis RPS andWISC-IV variables, the variance explainedwas
small (approximately 0.2%-0.4%) but comparable to other
studies42-44betweenthepsychosisRPSandIQorcognition.Our
datafurthersuggest that approximately0.8%to1.9%ofthevari-
ance inVSBOLDmaybeexplainedby thepsychosisRPS,which
is comparable toanother intermediatephenotypeRPSstudy.52
AlthoughtheVSBOLDvarianceexplainedbythepsychosisRPS
across thewhole samplewas small, comparing VS BOLD para-
meters estimates between the 1st and 10th deciles of the psy-
chosis RPS suggested a moderate effect size (Cohen d = 0.22-
0.49).Future studies should takeadvantageof largegenotyped
population cohorts to compare intermediate phenotypes for
individuals at either end of the RPS distribution.
One limitation of the study is that we did not have nega-
tivepsychosis symptommeasures for thebehavioralor imaging
genetic sample. Such measures would have proved useful in
exploring whether VS BOLD mediates the association be-
tween the psychosis RPS and negative symptoms. Currently,
it remains unknown whether the putative links among psy-
chopathologic conditions, negative symptoms, and VS BOLD
are mediated by common genetic risk factors. Although we
found associations between the psychosis RPS and depres-
sivesymptoms, theseassociationswere independentof theRPS
effects on VS BOLD, suggesting pleiotropic effects of genetic
psychosis susceptibility. Future work should explore the role
of VSBOLDduring reward anticipation as a candidatemecha-
nismbywhich thepsychosisRPSmaymediateeffectsonnega-
tive symptoms. Another limitation is that the association be-
tween the psychosis RPS and VS BOLD was in the opposite
directionof that expected, although this finding is in linewith
aprevious study50ofVSBOLDandgenetic risk for schizophre-
niaacrossadolescentdevelopment.Apreviousmeta-analysis12
suggests that psychosis is associatedwith attenuatedBOLD in
theVS,which is also linked tonegative symptoms.Becausewe
observed increasedVSBOLD, the link between psychosis and
psychosis symptom expression is less clear. We did not ob-
serve any association between the psychosis RPS and
impulsivity.32 This observationprovides no evidence of a role
in common risk for psychosis in the discounting of larger, fu-
turerewards, suggestingthatmyopicdiscountingmaybeastate
featureofpsychosis.However, these findingsmayhelp to iden-
tify the precise reward mechanisms that are altered because
of increased psychosis risk. We also acknowledge that sub-
stanceabuseanddependencemaybeconfounders in thestudy
of VS BOLD.
Conclusions
We observed negative associations between performance IQ
and thepsychosis RPSbut not behavioral impulsivity. Consis-
tent with our experimental hypothesis, we found associa-
tions between thepsychosis RPS andVSBOLD, primarily dur-
ing reward anticipation. We suggest that psychosis RPS may
play a role in shaping the reward response in the adolescent
brain, particularly duringperiods of reward sensitivity and in-
creased incentivemotivation.Future follow-up studieswill be
needed to assess how common genetic risk relates to (1) VS
BOLD in the adult brain, (2)whether psychosisRPS affects the
effect ofVSBOLDonnegative symptoms in adulthood, and (3)
whether environmental exposure (ie, cannabis use,53,54 early
life stressors55) attenuate these effects. Large neuroimaging
studies across multiple sites are well powered to determine
such effects and determine case-control differences in sub-
cortical volumes56-58 and facilitate novel gene discovery.59
These studies will aid in understanding the genetic and envi-
ronmental neurobiological mechanisms of negative symp-
toms, which are currently refractory to antipsychotic
medication.60 Future analysis of specific genetic risk path-
ways will help to elucidate the neurobiological mechanisms
that contribute to alterations of reward processing across the
psychosis spectrum and across the lifespan.
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